Selection of sedative drug in liver cirrhosis

Selection of sedative drug during upper GI endoscopy in cirrhotic patients to avoid minimal encephalopathy

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0002964

Enrollment

Registered

2018-06-29

Start date

2018-02-01

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : Patients with liver cirrhosis who underwent gastroscopy were randomly assigned to group 3 (midazolam group, propopol group, midazolam plus propofol group), and at least 2 hours after endoscopy

55kg, Age 65 &lt

: 1.5 mg (or 20&#37

reduction) Body weight 55 kg &lt

, Age &lt

65 : 2 mg (or 0.03 mg/kg) (B)Additional dose for maintenance 0.5 - 1 mg (or 0.02-0.03 mg / kg) is given at least every 2-3 minutes after checking respiration, oxygen saturation Maximum doses for rou

, Body weight &lt

55kg : 50&#37

dose reduction (B) Additional dose for maintenance 10 – 20 mg is given at least every 20-30 seconds after checking respiration, oxygen saturation Maximum doses for routine endoscopic sedation : 100

: 0.5 - 1.0 mg Body weight 55 kg &lt

65 : 1.5 – 2.0 mg (0.03 mg/kg) (B) Additional dose for maintenance: 20-30 mg Body weight &lt

: 50&#37

dose reduction 10 – 20 mg is given at least every 20-30 seconds after checking respiration, oxygen saturation ?Use of antidotes If the patient has lowered blood pressure or decreased oxygen saturatio

s judgment. Dosage: Administration of flumazenil 0.2 mg.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients diagnosed as liver cirrhosis from age 19-70, and child-pugh class A or B 2) Patients who are going to perform gastroscopy

Exclusion criteria

Exclusion criteria: 1) decompensated liver cirrhosis (Child-pugh class C) 2) history of overt hepatic encephalopathy 3) Evidence of gastrointestinal bleeding 4) Patients who are at risk for sedation with American Society of Anesthesiologists Classification (ASA Class) IV or higher 5) Patients who are anticipated to have a reduced sedative effect due to a history of taking anticonvulsant drugs within 4 weeks

Design outcomes

Primary

Measure	Time frame
Evaluation of minimal hepatic encephalopathy through a Stroop test	—

Secondary

Measure	Time frame
Vital sign;Subjective satisfaction of medical staff / patient	—

Countries

Korea, Republic of

Contacts

Public ContactJeong-Ju Yoo

Soon Chun Hyang University Hospital Bucheon

puby17@naver.com+82-32-621-5216

Outcome results